SCHEMBL1091702

SCHEMBL1091702

CC1(C)Cc2c([nH]c3c(F)c(-c4ccc(N5CCCCC5)cc4)ccc23)-c2ccc(NS(C)(=O)=O)cc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.39
EPHX2 P34913 3/20 0.39
NR1H4 Q96RI1 3/20 0.39
MPL P40238 5/20 0.38
PTK2 Q05397 1/20 0.36
MET P08581 1/20 0.36
GFER P55789 2/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MAPT P10636 2/20 0.35
RIPK2 O43353 1/20 0.34
ACVR1 Q04771 1/20 0.34
NOD2 Q9HC29 1/20 0.34
NR3C2 P08235 2/20 0.34
ALDH1A1 P00352 1/20 0.34
KMT2A Q03164 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
TDP2 O95551 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102218 0.86 MPL (0.51) GAAHPGDMAPK1EPHX2NR1H4
SCHEMBL1102210 0.84 MPL (0.46) GAAHPGDMAPK1EPHX2NR1H4
SCHEMBL1102077 0.73 MPL (0.69) GAAMPLGFERSMN1; SMN2MAPT
SCHEMBL1102282 0.73 MPL (0.49) GAAMAPK1MPLGFERSMN1; SMN2
SCHEMBL1102283 0.72 MPL (0.48) HPGDMAPK1MPLGFERLMNA
SCHEMBL1102085 0.72 MPL (0.57) GAAHPGDMAPK1MPLGFER
SCHEMBL1102143 0.71 MPL (0.57) MAPK1MPLSMN1; SMN2MAPTACVR1
SCHEMBL1102236 0.69 MPL (0.49) GAAHPGDMAPK1MPLGFER
SCHEMBL1091882 0.69 MPL (0.66) GAAHPGDMAPK1MPLGFER
SCHEMBL1102197 0.69 MPL (0.48) MAPK1MPLGFERSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153671-B2 Heterotetracyclic compounds as TPO mimetics IRM LLC (BM) 2012-04-10 US disclosed
US-8153671-B2 Heterotetracyclic compounds as TPO mimetics IRM LLC (BM) 2012-04-10 US disclosed
US-8153671-B2 Heterotetracyclic compounds as TPO mimetics IRM LLC (BM) 2012-04-10 US disclosed
EP-1910338-B1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2010-08-25 EP disclosed
EP-1910338-B1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2010-08-25 EP disclosed
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2009-03-19 US disclosed
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2009-03-19 US disclosed
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2009-03-19 US disclosed
WO-2007009120-A2 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS MPL, TPO, THPO GAA 1873/4885HPGD 1371/4885MAPK1 3575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.